A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

Cancer Research
Elena RatnerJoanne Weidhaas

Abstract

Ovarian cancer (OC) is the single most deadly form of women's cancer, typically presenting as an advanced disease at diagnosis in part due to a lack of known risk factors or genetic markers of risk. The KRAS oncogene and altered levels of the microRNA (miRNA) let-7 are associated with an increased risk of developing solid tumors. In this study, we investigated a hypothesized association between an increased risk of OC and a variant allele of KRAS at rs61764370, referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene. Specimens obtained were tested for the presence of the KRAS-variant from nonselected OC patients in three independent cohorts, two independent ovarian case-control studies, and OC patients with hereditary breast and ovarian cancer syndrome (HBOC) as well as their family members. Our results indicate that the KRAS-variant is associated with more than 25% of nonselected OC cases. Further, we found that it is a marker for a significant increased risk of developing OC, as confirmed by two independent case-control analyses. Lastly, we determined that the KRAS-variant was present in 61% of HBOC patients without BRCA1 or BRCA2 mutations, previously considered uninformative, as well as i...Continue Reading

References

Apr 17, 1997·The New England Journal of Medicine·J F StrattonB A Ponder
May 2, 2002·Nature Genetics·Paul D P PharoahBruce A J Ponder
Mar 16, 2005·Cell·Steven M JohnsonFrank J Slack
Mar 25, 2006·Nature Reviews. Cancer·Aurora Esquela-Kerscher, Frank J Slack
Mar 28, 2006·Future Oncology·Antonis C Antoniou, Douglas F Easton
Jul 18, 2006·Aging Cell·Carolina Ibáñez-VentosoMonica Driscoll
Sep 21, 2006·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Harvey A RischWenxin Zheng
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 17, 2009·The New England Journal of Medicine·John Hardy, Andrew Singleton
Apr 17, 2009·The New England Journal of Medicine·David B Goldstein
Apr 17, 2009·The New England Journal of Medicine·Joel N Hirschhorn
Oct 27, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·H H NelsonK T Kelsey

❮ Previous
Next ❯

Citations

Dec 14, 2011·Pathology Oncology Research : POR·Maria KoutsakiDemetrios A Spandidos
Jul 16, 2011·Hormones & Cancer·Dawn R CochraneJennifer K Richer
Mar 26, 2011·The Lancet Oncology·Madhu S Kumar, Charles Swanton
Aug 4, 2011·Proceedings of the National Academy of Sciences of the United States of America·Lina ZhangKexin Chen
Nov 28, 2012·Nucleic Acids Research·Anindya BhattacharyaYan Cui
Jun 4, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Jennifer Permuth-WeyUNKNOWN Ovarian Cancer Association Consortium (OCAC)
Mar 10, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paul D P PharoahUNKNOWN Ovarian Cancer Association Consortium
Apr 20, 2011·Breast Cancer Research : BCR·Erin N HoweJennifer K Richer
Oct 1, 2011·The Journal of Clinical Endocrinology and Metabolism·Rafaella PetraccoHugh S Taylor
Feb 7, 2012·EMBO Molecular Medicine·Olga GrechukhinaHugh S Taylor
Oct 12, 2013·Antioxidants & Redox Signaling·Thomas BerteroBernard Mari
Aug 22, 2013·Journal of Minimally Invasive Gynecology·João Siufi NetoMaurício Simões Abrão
Apr 30, 2014·Cell Biochemistry and Biophysics·Pingjiang YeTao Liu
Apr 26, 2013·Critical Reviews in Oncogenesis·Carina Preskill, Joanne B Weidhaas
Dec 10, 2014·Expert Review of Molecular Diagnostics·Sudhir Perincheri, Pei Hui
Dec 1, 2014·Journal of Hematology & Oncology·Minlee Kim, Frank J Slack
Apr 10, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ting-Yan ShiQingyi Wei
Aug 3, 2011·The Lancet Oncology·Paul PharoahJonathan Tyrer
Mar 23, 2011·Translational Research : the Journal of Laboratory and Clinical Medicine·S Patrick Nana-Sinkam, Carlo M Croce
Mar 1, 2011·Trends in Molecular Medicine·Elcie ChanJoanne Barnes Weidhaas
May 1, 2013·International Journal of Cancer. Journal International Du Cancer·Yue JiangHongbing Shen
Oct 10, 2013·Journal of Cellular Physiology·Sabita N Saldanha, Trygve O Tollefsbol
May 12, 2015·Cell Cycle·Terri P McVeighJoanne B Weidhaas
Dec 10, 2013·Journal of Ovarian Research·Huanchun YingQing Yang
Oct 4, 2014·Genes, Chromosomes & Cancer·Casina W S KanDeborah J Marsh
Jun 7, 2011·Biochimica Et Biophysica Acta·M G M BraemN C Onland-Moret
Apr 26, 2011·Pharmacology & Therapeutics·Elena Sotillo, Andrei Thomas-Tikhonenko
May 6, 2011·Cell Cycle·Elcie ChanJoanne Barnes Weidhaas
Jun 18, 2014·Urologic Oncology·William ThieuChristopher P Evans
Mar 20, 2012·Cell·Joshua T Mendell, Eric N Olson
Aug 17, 2014·Cancer Epidemiology·Kim De RuyckHubert Thierens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.